Clinical Trial Detail

NCT ID NCT03179917
Title Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.